Is Medibank Private Ltd one of the best blue-chip shares to buy?

Medibank Private Ltd (ASX:MPL) has been one of the top-performing blue chip shares over the last 12 months but is it too late to buy?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last week was an eventful week for Medibank Private Ltd (ASX: MPL) shareholders after it was revealed that the Australian Competition and Consumer Commission (ACCC) would take legal action against the private health insurer for misleading consumers.

The shares plunged more than 8% on the day of the announcement, but managed to claw back some of those losses throughout the rest of the week as investors took some time to absorb the news.

Despite last week's setback, those shareholders who have held onto their shares since Medibank floated in December 2014 would be pretty happy. The shares have managed to increase by nearly 36% since listing, and as the chart below highlights, they have outperformed the broader market significantly.

Source: Google Finance
Source: Google Finance

The shares have performed well over the past 12 months in particular, and surprisingly, Medibank has been the second best performing large-cap stock during that period. Only gold miner, Newcrest Mining Limited (ASX: NCM), has put in a better performance.

Is Medibank a buy at $2.95 per share?

There are a number of reasons you could be bullish or bearish on Medibank right now.

Some of the reasons I would avoid Medibank include:

Sluggish Revenue Growth – Although Medibank recorded a strong rise in first half profits, the majority of the gains were made through cost savings. Revenue increased by only 4.6% with the company blaming slowing growth across the industry and higher churn rates. This sluggish revenue growth may become a serious problem in the future as there will come a time when cost saving measures no longer have an impact.

Higher customer premiums – The cost of healthcare is expected to significantly outpace the rate of inflation over the long term based purely on the dynamics of supply and demand. Inevitably, private health insurers will have to pass on these costs and this will put more pressure on premiums which could deter some people from having private health insurance. Worryingly, Medibank reported a 1.2% decline in policyholder growth in the first half and a significant increase in its customer lapse rate.

Valuation – Medibank shares are currently trading on a price-to-earnings ratio of around 21. This is not particularly cheap unless you are confident the company will continue to strip out costs in a bid to drive earnings growth.

Some of the reasons I would buy Medibank include:

Potential for further short-term cost savings – Medibank's first half results showed the company made solid progress in reducing costs by clamping down on fraudulent claims and by negotiating better pricing with hospitals. The company is expected to improve operating margins by squeezing out further cost savings and this should help to support earnings in the short term.

Solid dividend – Investors can be pretty confident that Medibank will pay a solid dividend for the foreseeable future. At the current share price, investors can expect a fully franked dividend yield of around 3.6%.

Debt free balance sheet – Medibank has no long term debt on its balance sheet which means the company is in a fairly healthy financial position.

Foolish takeaway

Based on the points above, I would be inclined to avoid Medibank shares for the time being as the company is losing policyholders and cost savings can only go so far in the short term.

If the shares become cheaper or top line growth begins to accelerate, I would be far more confident in becoming a shareholder of the company.

Motley Fool contributor Christopher Georges has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »